Analysis of the Pathological Progression of Severe Community-Acquired Pneumonia Based on Serum Inflammatory Markers HMGB-1, IL-1β, and IL-6: A Propensity Score Matching Study

  • Junwei Zhang Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
  • Tong Liu Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
  • Wei Xi Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
  • BaYaEr WuLiJie Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
  • Lingyun Qiu Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
  • Jianjun Shuai Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
  • Fan Yang Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
  • Xingang Wang Department of Medical Imaging, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
DOI: https://doi.org/10.5937/jomb0-58952
Keywords: community-acquired pneumonia, severe pneumonia, HMGB1, interleukin, CT

Abstract


Objective: This study aimed to evaluate the involvement of serum inflammatory markers—high-mobility group box 1 (HMGB-1), interleukin-1β (IL-1β), and interleukin-6 (IL-6)—in the pathological progression of severe community-acquired pneumonia (SCAP), examine their association with computed tomography (CT) scores, and assess their combined utility for diagnosis and outcome prediction.

Methods: We performed a propensity score-matched retrospective cohort study involving 164 SCAP patients (research group) and 164 age- and sex-matched healthy controls (control group) enrolled between March 2024 and January 2025. Serum HMGB-1, IL-1β, and IL-6 concentrations were quantified by enzyme-linked immunosorbent assay (ELISA), while pulmonary radiographic findings was evaluated using the Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) scoring system. Comparative analyses of inflammatory markers and CT imaging findings were conducted, with subsequent correlation studies, receiver operating characteristic (ROC) curve analysis, and multivariate regression modeling to determine their relationship with in-hospital mortality.

Results: Following propensity score matching, demographic characteristics were well-balanced between groups (standardized mean differences <0.1). SCAP patients demonstrated significantly elevated serum levels of HMGB-1, IL-1β, and IL-6 (P<0.05), along with higher CT scores than controls. Strong positive correlations were observed between inflammatory marker concentrations and CT scores (P<0.05). The combination of inflammatory markers and CT scoring showed enhanced diagnostic discrimination for SCAP (area under the curve [AUC]=0.9342) and superior predictive value for in-hospital mortality (AUC=0.9348) compared to individual parameters (P<0.05). Multivariate analysis identified the elevation of these biomarkers as independent predictors of mortality in SCAP patients (P<0.05).

Conclusion: HMGB-1, IL-1β, and IL-6 play pivotal roles in promoting SCAP progression by driving inflammatory cascades and pulmonary tissue injury. The integrated assessment of these biomarkers with CT scoring significantly improves disease monitoring and prognostic assessment accuracy, potentially guiding individualized anti-inflammatory interventions in SCAP management.

Published
2025/06/25
Issue
Ahead of print
Section
Original paper

Copyright (c) 2025 Junwei Zhang, Tong Liu, Wei Xi, BaYaEr WuLiJie, Lingyun Qiu, Jianjun Shuai, Fan Yang, Xingang Wang

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.